THE DEAL, AT A GLANCE
1/4 reviewedAstrocyte
Astrocyte
Astrocyte develops brain-protecting therapies for concussion, traumatic brain injury and stroke.
Astrocyte raised $9.5M Series B, announced 2026-10-0201What it doesAstrocyte develops brain-protecting therapies for concussion, traumatic brain injury and stroke.Source-grounded · automated review · Explore ↗
Checked 2026-10-03 · Review due 2026-10-10
Read supporting source ↗Astrocyte Pharmaceuticals Inc. , a…
02Who is involvedBacked by DeepWork Capital, the complicated mild TBIFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedAstrocyte raised $9.5M Series B, announced 2026-10-02From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersAstrocyte's $9.5M Series B funds AST-004 as it nears concussion data, positioning the company around a cerebroprotective candidate designed to target astrocytes and…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
Astrocyte · Financing Record
Explore source-linked visual explanations for Astrocyte. Unsupported claims are withheld while source review continues.
Record 13288 · Recorded date: 2026-10-02
Explore company records →